According to market projections, the lung disease therapeutics sector is expected to grow from USD 102.85 billion in 2026 to USD 175.25 billion by 2035, reflecting a CAGR of 6.1%. Lung disease therapeutics focus on treating conditions like asthma, COPD, pulmonary fibrosis, and infections. These treatments include inhalers, medications, oxygen therapy, and advanced options like biologics and gene therapy. The goal is to improve breathing, reduce symptoms, and enhance patients' quality of life.
Last Updated : 03 August 2026Category: Therapeutic AreaInsight Code: 5066Format: PDF / PPT / Excel
Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
Asthma
Lung Cancer
Chronic Obstructive Pulmonary Disease (COPD)
Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
Corticosteroids
Bronchodilator
Antimicrobial
Alkylating Agents
Mucolytics
Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
Small molecules
Biologics
Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Asia-Pacific Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
Online
Hospital
Retail
Latin America Lung Disease Therapeutics Market Assessment
Overview
Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
Asthma
Lung Cancer
Chronic Obstructive Pulmonary Disease (COPD)
Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
Corticosteroids
Bronchodilator
Antimicrobial
Alkylating Agents
Mucolytics
Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
Small molecules
Biologics
Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Latin America Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
Online
Hospital
Retail
Middle East and Africa Lung Disease Therapeutics Market Assessment
Overview
Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Disease Type (2021 – 2033)
Asthma
Lung Cancer
Chronic Obstructive Pulmonary Disease (COPD)
Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
Corticosteroids
Bronchodilator
Antimicrobial
Alkylating Agents
Mucolytics
Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Molecule Type (2021 – 2033)
Small molecules
Biologics
Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Treatment Type (2021 – 2033)
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Middle East and Africa Lung Disease Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
Online
Hospital
Retail
Company Profiles
Johnson & Johnson
Company Overview
Geographic Footprints
Financial Performance
Product Portfolio
SWOT Analysis
R&D Efforts
Recent Developments & Strategic Collaborations
Product Launch/M&A/Technical Collaboration
Amgen Inc.
AstraZeneca
Boehringer Ingelheim
Pfizer Inc.
Allergan Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Hoffmann-La Roche
Merck & Co
Teva Pharmaceutical Industries Ltd.
AbbVie, Inc.
Novartis AG
Conclusion & Recommendations
FAQ's
Answer : Lung disease therapeutics market stands at USD 102.85 billion in 2026 and is expected to reach USD 175.25 billion by 2035, growing at a CAGR of 6.1% from 2026 to 2035.
Answer : Several factors contribute to the growth of the lung disease therapeutics market, including the increasing prevalence of lung diseases worldwide, rising aging population, growing awareness about respiratory health, technological advancements in diagnostics and treatment options, and the development of targeted therapies. Additionally, lifestyle changes, environmental factors, and the impact of air pollution also play a role in the increasing demand for lung disease therapeutics.
Answer : While the growth prospects may vary across different segments, chronic obstructive pulmonary disease (COPD) is expected to witness significant growth in the forecast period. COPD is a leading cause of morbidity and mortality globally, and the rising prevalence of smoking and environmental pollutants contributes to the increasing burden of COPD cases, driving the demand for effective therapeutics.
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare
market research. As a content reviewer, Aditi ensures the quality and accuracy of all market
insights and data presented by the research team.
We use cookies that are necessary to make our site work. We may also use additional cookies to analyze,
improve, and personalize our content and your digital experience.
You can manage your cookie preferences using the
Privacy Policy
For more information, see our
Terms and Conditions
.
Cookie Preference Center
We use cookies which are necessary to make our site work.
We may also use additional cookies to analyze, improve and personalize
our content and your digital experience.
For more information, please read our
Cookie Policy
.
You may choose not to allow some types of cookies.
Blocking some cookies may impact your experience of the site.
sales@towardshealthcare.com
+1 804-441-9344
Download Sample
USA : +1 8044 419344
sales@towardshealthcare.com